SFM
ENTA icon

Systematic Financial Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Systematic Financial Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-6,380
Closed -$320K – 313
2020
Q2 		$320K Buy
+6,380
New +$330K 0.02% 313
2020
Q1 		– Sell
-9,785
Closed -$605K – 501
2019
Q4 		$605K Buy
9,785
+2,155
+28% +$134K 0.02% 348
2019
Q3 		$458K Sell
7,630
-1,975
-21% -$147K 0.02% 416
2019
Q2 		$810K Buy
+9,605
New +$864K 0.03% 450

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Systematic Financial Management's ENTA Position: Q3 2020 in Review

Systematic Financial Management sold out of Enanta Pharmaceuticals (ENTA) in Q3 2020, closing a stake of 6,380 shares — an estimated $320K sold.

Systematic Financial Management first reported a position in ENTA in Q2 2019 and held it in 4 quarters. The position peaked at $810K in Q2 2019. 172 funds tracked by Wall St. Rank hold ENTA as of Q3 2020.

  • Systematic Financial Management reported no remaining Enanta Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Systematic Financial Management sold 6,380 Enanta Pharmaceuticals shares in Q3 2020, an estimated $320K.
  • Systematic Financial Management first reported a position in Enanta Pharmaceuticals in Q2 2019 and held it in 4 quarters.
  • Systematic Financial Management's Enanta Pharmaceuticals position peaked at $810K in Q2 2019.
  • 172 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2020.

Based on Systematic Financial Management's 13F filing for Q3 2020, filed 12 Nov 2020.